Actinium Pharmaceuticals, Inc. (7AY1.F)

7,32 +0,09 (+1,18%) Börsenschluss: 08:00AM CEST

Actinium Pharmaceuticals, Inc.

100 Park Avenue
23rd Floor
New York, NY 10017
United States
646 677 3870
https://www.actiniumpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 49

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Sandesh C. Seth M.B.A., M.S.	Chairman & CEO	1,12M	N/A	1964
Mr. Steven O'Loughlin BS	CFO & Corporate Secretary	549,04k	N/A	1986
Dr. Paul Diamond Esq., Ph.D.	Vice President of Patent & Legal Counsel	N/A	N/A	N/A
Dr. Avinash Desai M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Jenny Hsieh	Chief Strategy Officer	N/A	N/A	N/A
Ms. Sunitha Lakshminarayanan	Senior VP, Head of CMC & Product Development	N/A	N/A	N/A
Ms. Caroline Yarbrough	Chief Commercial Officer	N/A	N/A	N/A
Ms. Lynn M. Bodarky M.B.A.	Chief Business Officer	N/A	N/A	1966
Mr. J. C. Simeon	Executive Director of Quality Assurance	N/A	N/A	N/A
Dr. Madhuri Vusirikala M.D.	Vice President of Clinical Development BMT & Cellular Therapy	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Corporate Governance

Actinium Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 6, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.